Study Finds Population Differences Between Randomized Controlled Trials, Real-World Studies of Ranibizumab


DME patients in non-interventional studies notably older than in RCTs.

Randomized controlled trials, or RCTs, have strict inclusion and exclusion criteria that can limit the applicability of their findings in routine clinical practice. In contrast, non-interventional studies often include non-typical patients, those with comorbidities, or atypically old or young patients. In addition, the study group in non-interventional studies may comprise a greater range of disease stages.

Thus, non-interventional studies can obtain more generalizable data on the effectiveness of treatments than RCTs can. Moreover, non-interventional studies can provide a more accurate picture of the long-term safety and tolerability of treatments in the real world.

Because most diseases treated with anti-vascular endothelial growth factor (anti-VEGF) agents are age-dependent and often accompanied by substantial comorbidities, age and comorbidity status can be particularly influential in studies of these agents. And because the life expectancy of women is greater than that of men, these retinal diseases are more likely to develop in women, so sex as well as age affects their occurrence and management.

In addition, baseline values may affect treatment responses. Researchers refer to this influence as the ceiling effect: The better a patient’s visual acuity when treatment begins, the more improvement can be expected. The potential impact of the ceiling effect indicates the need for research in all patient subgroups.

The prospective, non-interventional, open-label OCEAN study of the anti-VEGF agent ranibizumab (Lucentis/Roche) is the largest German observational study pursued in ophthalmology so far. OCEAN stands for Observation of treatment patterns with LuCEntis and real-life ophthalmic monitoring, including optional optical coherence tomography (OCT), in Approved iNdications.

Because OCEAN is a non-interventional study, it includes a broader spectrum of patients and has more variability of patients than RCTs do. Therefore, OCEAN may provide valuable data on how to manage patients who are more representative of those in the real world than RCT patients are.

The OCEAN investigators recently compared the baseline characteristics by indication of the 5,606 patients enrolled in their study with those of patients in published RCTs to determine how these baseline characteristics differ. Treatment indications in OCEAN were neovascular age-related macular degeneration (nAMD) in 3,614 patients, diabetic macular edema (DME) in 1,211, and retinal vein occlusion (RVO) in 741.

The OCEAN investigators then calculated confidence intervals (CIs) for the presence of the baseline characteristics and assessed statistically significant differences in these CIs for each type of study as indicated by non-overlap. To make this comparison, the study group searched the literature to select relevant RCTs. They found 13 nAMD trials, 9 DME trials, and five RVO trials they deemed suitable for comparison.

The investigators found that, for patients with DME, the mean age of the OCEAN patients was statistically significantly higher than that of the RCT patients. In contrast, the sex distribution of the study group in OCEAN was comparable with those in the RCTs for all indications.

Moreover, for nAMD and DME, the investigators found notable differences in baseline visual acuity between study groups in OCEAN and in the RCTs. Mean baseline visual acuity was significantly higher in some RCTs and lower in other RCTs than in OCEAN.

“Across the trials and indications, the results from OCEAN tended to show higher or similar SDs [standard deviations] than the RCT data” in patient characteristics, the OCEAN study group noted. Findings from their demographic study also led them to highlight the complementarity of non-interventional studies and RCTs.

A report on the study, “Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials,” was recently published online in BMC Ophthalmology.

Related Coverage:

Trial Examines Ranibizumab Injections and Vascular Pigment Epithelial Detachment in AMD Patients

Recent Trial: Ranibizumab Did Not Prevent New Macular Atrophy in Cases of Neovascular AMD

Wet AMD Treatment Outcomes Look Misleadingly Better in Clinical Trials

Related Videos
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Etienne Sibille, PhD: Innovations in Cognitive Pathology
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.